Abstract
Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive effector, and its expression is associated with prognosis in several cancer types. Here, we investigated the relationship between IDO1 expression in lung adenocarcinoma and patient prognosis and clinicopathological features, including programmed cell death-ligand 1 (PD-L1) expression. In this study, surgically resected primary lung adenocarcinoma specimens from 427 patients were evaluated for IDO1 and PD-L1 expression by immunohistochemistry, and lung adenocarcinoma cell lines were evaluated for IDO1 and PD-L1 protein expression by enzyme-linked immunosorbent assay and flow cytometry and for messenger RNA levels by real-time reverse-transcriptase polymerase chain reaction analysis. IDO1 was expressed in 260 patients (60.9%) at 1% cut-off and 63 patients (14.8%) at 50% cut-off. Tissues from 145 patients (34.0%) were positive for PD-L1 using the cut-off of 1%. Multivariate analysis showed that ≥1% IDO1 positivity was significantly associated with higher tumour grade, vascular invasion and PD-L1 expression. IDO1 and PD-L1 proteins were co-expressed in 123 patients (28.8%), and co-expressing tumours exhibited significantly more malignant traits than those positive for one...Continue Reading
Citations
Feb 6, 2019·Cancers·Sha ZhouMian Xi
Jun 5, 2019·PloS One·Kazuki TakadaMasaki Mori
Mar 7, 2020·International Journal of Cancer. Journal International Du Cancer·Matthew D HellmannRebecca S Heist
Sep 21, 2020·Journal of Cancer Research and Clinical Oncology·Takeshi IwasakiYoshinao Oda
Jun 17, 2020·Frontiers in Immunology·Martina MandaranoAngelo Sidoni
May 15, 2020·Journal of Cancer Research and Clinical Oncology·Kazuki TakadaMasaki Mori
Oct 28, 2018·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·M Lisa ZhangMari Mino-Kenudson
May 11, 2020·Journal of Cancer Research and Clinical Oncology·Yu TodaYoshinao Oda
Nov 21, 2019·Molecular Medicine Reports·Meng LiuHongmei Wang
Jun 20, 2020·Scientific Reports·Daniel C LieblerAaron M Gruver
Sep 19, 2020·Chinese Medical Journal·Hao-Hua ZhuXing-Sheng Hu
Jul 11, 2020·Cell·Michael A GilletteUNKNOWN Clinical Proteomic Tumor Analysis Consortium
Sep 10, 2019·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Ryota SumitomoCheng-Long Huang
Oct 15, 2019·European Journal of Medicinal Chemistry·Yi ZouYisheng Lai
Feb 10, 2021·Journal of Experimental & Clinical Cancer Research : CR·Yu YaoQing Yang
Apr 23, 2021·Journal of Hematology & Oncology·Kai TangBin Yu
Jul 22, 2021·Scientific Reports·Yu TodaYoshinao Oda